Stock News

Immune Design Corp. (IMDZ) Reaches $4.03 After 3.00% Up Move; SuperGroup Plc (LON:SGP) Had 8 Bullish Analysts

The stock of Immune Design Corp. (NASDAQ:IMDZ) is a huge mover today! The stock increased 8.78% or $0.325 during the last trading session, reaching $4.025. About 128,024 shares traded. Immune Design Corp. (NASDAQ:IMDZ) has declined 40.11% since December 7, 2016 and is downtrending. It has underperformed by 56.81% the S&P500.The move comes after 7 months positive chart setup for the $193.44M company. It was reported on Dec, 7 by Barchart.com. We have $4.15 PT which if reached, will make NASDAQ:IMDZ worth $5.80 million more.

Among 14 analysts covering SuperGroup (LON:SGP), 8 have Buy rating, 2 Sell and 4 Hold. Therefore 57% are positive. SuperGroup had 123 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, May 11 by Liberum Capital. The firm earned “Buy” rating on Friday, November 27 by Canaccord Genuity. The stock has “Outperform” rating by RBC Capital Markets on Thursday, January 12. Liberum Capital maintained SuperGroup Plc (LON:SGP) rating on Thursday, July 14. Liberum Capital has “Buy” rating and GBX 1500 target. The stock of SuperGroup Plc (LON:SGP) earned “Buy” rating by Peel Hunt on Wednesday, April 13. On Monday, August 1 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Monday, February 15 the stock rating was maintained by Peel Hunt with “Buy”. On Monday, August 17 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Hold” rating by Numis Securities on Wednesday, January 27. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, July 14. See SuperGroup Plc (LON:SGP) latest ratings:

05/12/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 2100.00 New Target: GBX 2100.00 Maintain
21/11/2017 Broker: Deutsche Bank Rating: Hold New Target: GBX 1990.00 Initiates Starts
17/11/2017 Broker: RBC Capital Markets Rating: Sector Performer Old Target: GBX 1800.00 New Target: GBX 1900.00 Downgrade
09/11/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 2100.00 New Target: GBX 2100.00 Maintain
03/11/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 2100.00 New Target: GBX 2100.00 Maintain
04/10/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 1900.00 New Target: GBX 2100.00 Maintain
27/09/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 1900.00 New Target: GBX 1900.00 Maintain
15/09/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 1900.00 New Target: GBX 1900.00 Maintain
25/08/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 1750.00 New Target: GBX 1750.00 Maintain
14/08/2017 Broker: Barclays Capital Rating: Underweight Maintain

Among 5 analysts covering Immune Design (NASDAQ:IMDZ), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Immune Design had 10 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Immune Design Corp. (NASDAQ:IMDZ) has “Buy” rating given on Monday, June 26 by Jefferies. Leerink Swann initiated Immune Design Corp. (NASDAQ:IMDZ) on Tuesday, August 18 with “Outperform” rating. The company was maintained on Wednesday, October 18 by Wells Fargo. The firm has “Buy” rating by Jefferies given on Wednesday, August 10. The stock of Immune Design Corp. (NASDAQ:IMDZ) earned “Buy” rating by Jefferies on Monday, September 4. The rating was maintained by Cowen & Co with “Buy” on Tuesday, June 6. On Thursday, October 5 the stock rating was maintained by Jefferies with “Buy”. On Wednesday, September 9 the stock rating was initiated by Jefferies with “Buy”.

Analysts await Immune Design Corp. (NASDAQ:IMDZ) to report earnings on March, 6. They expect $-0.39 earnings per share, up 31.58% or $0.18 from last year’s $-0.57 per share. After $-0.52 actual earnings per share reported by Immune Design Corp. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Investors sentiment increased to 2.44 in 2017 Q2. Its up 1.44, from 1 in 2017Q1. It improved, as 8 investors sold Immune Design Corp. shares while 8 reduced holdings. 13 funds opened positions while 26 raised stakes. 10.96 million shares or 2.86% more from 10.66 million shares in 2017Q1 were reported. Millennium Mngmt Limited Com owns 144,534 shares. 20,100 were reported by State Common Retirement Fund. Focused Wealth Inc has invested 0.04% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Rhumbline Advisers has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Schwab Charles Invest Management Inc invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Franklin Resources has 760,253 shares for 0% of their portfolio. Wells Fargo Mn accumulated 218,700 shares. D E Shaw Company holds 0% or 20,122 shares. Alliancebernstein Lp, New York-based fund reported 12,100 shares. Moreover, Victory Cap Inc has 0.05% invested in Immune Design Corp. (NASDAQ:IMDZ) for 1.98M shares. Moreover, State Of Wisconsin Invest Board has 0% invested in Immune Design Corp. (NASDAQ:IMDZ). Cormorant Asset Mngmt Ltd Liability Com has invested 0.54% in Immune Design Corp. (NASDAQ:IMDZ). Dimensional Fund Limited Partnership reported 0% in Immune Design Corp. (NASDAQ:IMDZ). Personal Cap Corp accumulated 36,500 shares. Northern Trust Corporation holds 180,877 shares.

SuperGroup Plc engages in the design, production, and sale of clothing and accessories primarily under the Superdry brand for men and women worldwide. The company has market cap of 1.58 billion GBP. It operates through two divisions, Retail and Wholesale. It has a 23.99 P/E ratio. The Retail segment operates stores, concessions, and various Internet sites, which sell companyÂ’s own brand and third party clothing, footwear, and accessories in the United Kingdom, the Republic of Ireland, Europe, and the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *